Blood Plasma Reveals Cancer

Quest Diagnostics Inc. has launched the first of its Leumeta cancer testing assays, designed as an alternative to bone marrow biopsies (which everyone would prefer to avoid). The assays identify and analyze genetic components of leukemia and lymphoma tumors using blood plasma instead of bone marrow, and can measure the amount of cancer in a patient, detect certain blood cancer markers, and assist the physician in monitoring the efficacy of the treatment being administered. (www.sensorsmag.com/0706/RDPlasma)

Suggested Articles

Renesas has introduced an evaluation and prototyping kit that will speed time-to-market to create secure end-to-end IoT cloud solutions for sensor-based…

MarketsandMarkets says the low-light imaging market is expected to grow from $10.04 billion in 2019 to $18.36 billion by 2024.

SiC can make medical devices more perceptive, it can make electronics more energy-efficient, and it can help sensors perform in higher temperatures.